Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT02462525

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02462525. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with relapsed and refractory multiple myeloma.

Study identification

NCT ID: NCT02462525
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: AbbVie; Industry
Enrollment: 74 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 6, 2015 (Actual)
Primary completion: Dec 6, 2017 (Actual)
Completion: Dec 6, 2017 (Actual)
Last update posted: Sep 13, 2018

2015 – 2017

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
The University of Chicago Medical Center /ID# 139403	Chicago	Illinois	60637	—
University of Michigan Medical Center /ID# 139402	Ann Arbor	Michigan	48109	—
Washington University School of Medicine /ID# 135708	St Louis	Missouri	63110-1093	—
Mount Sinai Medical Center /ID# 133569	New York	New York	10029	—
The Sarah Cannon Research Institute /ID# 135814	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02462525, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 13, 2018 · Synced Nov 15, 2026